HIV Prevention, Testing, PrEP and PEP

HIV prevention is strongest when several tools work together: condoms, sterile injection equipment, regular testing, PrEP for ongoing risk, and PEP after a possible recent exposure. Treatment also prevents transmission when viral load remains undetectable.

PEP is time-sensitive and should be started as soon as possible within 72 hours after a possible exposure. PrEP is planned prevention for people with ongoing risk and requires periodic HIV, kidney, and STI monitoring.

Testing windows vary by test type. A negative result immediately after exposure does not always exclude infection, so follow-up testing is important. Partners should avoid blame and focus on care, testing, and prevention.

HIV is a manageable chronic condition with treatment. Early diagnosis protects health, prevents transmission, and reduces fear created by outdated misinformation.

Layers of HIV prevention

Effective HIV prevention combines several tools: consistent condom use, PrEP for those at higher risk, regular testing, and treatment as prevention—when a person living with HIV is on effective treatment with an undetectable viral load, they cannot transmit the virus sexually (undetectable equals untransmittable). Understanding these layers lets people build a plan that fits their life.

Testing and emergency options

Everyone should test at least once, with more frequent testing for those at higher risk; rapid and self-test options make this easier and more private. After a possible exposure, PEP—a short course of medication started within 72 hours—can prevent infection. Early diagnosis leads to treatment that protects health and prevents onward transmission.

Understanding HIV Transmission Routes

HIV is transmitted through contact with specific body fluids from a person living with HIV who has a detectable viral load: blood, semen (including pre-ejaculatory fluid), rectal secretions, vaginal secretions, and breast milk. Transmission requires one of these fluids to enter the bloodstream, mucous membranes, or damaged tissue of another person. The most efficient routes are receptive anal sex (the highest per-act risk among sexual exposures), sharing needles or syringes, and mother-to-child transmission during pregnancy, birth, or breastfeeding.

HIV is not transmitted through casual contact: hugging, kissing, sharing utensils or toilet seats, sneezing, coughing, mosquitoes, or water. These facts matter because pervasive myths about casual transmission fuel stigma and fear without any epidemiological basis. Understanding the actual transmission mechanism allows people to focus prevention efforts where they genuinely matter.

The Prevention Toolkit: Layers of Protection

No single prevention strategy is 100% effective, but combining tools creates a protective framework that approaches that goal. Consistent and correct use of external condoms reduces sexual HIV transmission risk by approximately 80–90% per act. PrEP, when taken daily, reduces risk by up to 99%. Undetectable = Untransmittable (U=U): a person living with HIV who takes antiretroviral therapy and maintains an undetectable viral load cannot sexually transmit the virus. This is one of the most powerful statements in modern HIV science and is backed by the PARTNER, Opposites Attract, and HPTN 052 studies.

Combining prevention layers — such as a virally suppressed positive partner, the negative partner on PrEP, and condom use during STI risk periods — represents the current pinnacle of sexual HIV prevention available to couples where one partner is positive. For people who inject drugs, using sterile injection equipment (through needle exchange programs) eliminates transmission via that route entirely. PrEP also covers this route for people who are unable to access sterile equipment consistently.

HIV Testing: Types and What They Detect

Fourth-generation antigen/antibody (Ag/Ab) combination tests detect both the p24 antigen (a viral protein present before antibodies develop) and HIV antibodies. These are the standard recommended tests for clinical settings and can detect most infections within 18–45 days of exposure. The window period for this generation of test closes by 45 days in the vast majority of people and definitively by 90 days. Nucleic acid amplification tests (NATs/NAATs) detect HIV RNA directly and can identify infection as early as 10–33 days post-exposure; they are used in blood banking and when very early detection is needed.

Rapid antibody tests — available for point-of-care use and in home-testing kits — detect HIV antibodies only, which means they have a longer window period of up to 90 days. OraQuick, the FDA-approved over-the-counter home test, uses an oral swab and provides results in 20 minutes. A negative result on a rapid test should be confirmed with a laboratory test if it falls within the window period after a potential exposure. Positive rapid results always require confirmatory laboratory testing before a diagnosis is made.

Post-Exposure Prophylaxis (PEP): The Emergency Option

PEP is a course of antiretroviral medication taken after a potential HIV exposure to prevent infection from establishing. It must be started within 72 hours of exposure — the sooner the better, with each passing hour reducing effectiveness. PEP is taken for 28 days. It is highly effective when started promptly and taken consistently, but it is not 100% effective and is intended as an emergency measure rather than a routine prevention strategy.

PEP is appropriate after unprotected anal or vaginal sex with a partner of unknown or HIV-positive status (particularly if not virally suppressed), after a condom breaks during sex with such a partner, after sharing needles, or after a occupational exposure (healthcare workers with needlestick injuries have access to employer-provided PEP). Emergency departments, urgent care centers, HIV clinics, and some pharmacies can prescribe PEP. In the United States, the HRSA HIV/AIDS Bureau provides resources for locating PEP quickly. The 72-hour window makes this genuinely urgent — going to sleep and planning to seek PEP in the morning after an exposure that occurred at night loses critical time.

Living With HIV Today: Treatment as Prevention

Antiretroviral therapy (ART) has transformed HIV from a fatal diagnosis to a manageable chronic condition. Modern regimens are often a single pill taken once daily, with minimal side effects and excellent tolerability. People who start treatment early, adhere to it consistently, and achieve viral suppression have life expectancy approaching that of HIV-negative peers. The goal of treatment — achieving and maintaining an undetectable viral load, generally defined as under 200 copies/mL — is typically reached within three to six months of starting effective therapy.

The U=U message is not merely reassuring to people living with HIV and their partners — it is a prevention tool. Every person with HIV who achieves and maintains viral suppression through ART is effectively removed from the transmission chain. Expanding access to testing and treatment globally is therefore one of the most powerful HIV prevention interventions available at the population level, which is why UNAIDS's 95-95-95 targets (95% of people with HIV knowing their status, 95% of those on treatment, 95% of those virally suppressed) are central to global HIV-elimination strategies.

Stigma and Testing Barriers

HIV-related stigma remains one of the most significant barriers to testing, treatment initiation, and disclosure. Fear of discrimination — in relationships, employment, healthcare, and family — leads many people to avoid testing, preferring not to know. This is epidemiologically costly: people who do not know their HIV-positive status cannot access treatment, are not benefiting from U=U, and may inadvertently transmit to partners. Normalizing routine HIV testing as part of general healthcare — rather than framing it as something only high-risk or suspect people do — reduces the stigmatising signal.

At-home testing has meaningfully reduced the stigma barrier for many people by removing the social exposure of a clinic visit. Healthcare providers who discuss HIV testing matter-of-factly, as part of general health screening, contribute to destigmatization. Community-based organizations and LGBTQ+ health centers often provide culturally affirming HIV testing environments that feel safe for populations that have historically experienced discrimination in mainstream healthcare.

Frequently Asked Questions

If my partner is on ART and undetectable, do I still need PrEP? This is a personal decision informed by several factors. U=U is scientifically robust for a partner who is consistently undetectable and engaged in regular monitoring. However, viral load can temporarily increase (blips) if doses are missed or during illness, and some people choose PrEP as an additional layer of reassurance. The decision depends on relationship dynamics, how consistently the HIV-positive partner maintains undetectable status, and individual risk tolerance. A frank conversation with a sexual health clinician can help.

How long after a negative HIV test can I trust the result? Using a fourth-generation Ag/Ab test, a negative result at 45 days post-exposure is highly reliable; at 90 days it is conclusive for nearly all people. If you used a rapid antibody-only test, 90 days is the accepted window before a definitive negative result. Some sources cite 12 weeks (about 84 days) as the window period; 90 days is a commonly used conservative round number that applies in the vast majority of cases.

Does PEP have side effects, and will it affect my daily life? PEP regimens commonly cause nausea, fatigue, and headache during the 28-day course, though not everyone experiences these. Taking medication with food reduces nausea. The side effects are generally manageable and worth tolerating given the stakes. Completing the full 28-day course is essential — stopping early significantly reduces effectiveness. Some people find it helpful to set a daily phone alarm for the same time each day to maintain adherence.